PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Active, not recruiting · Phase 2 · NCT01589302
Conditions: Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
At a glance
- Research payments reported, 2025
- $1.0M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 154
About the trial
- Sponsor
- Kami Maddocks, MD
- Tested
- ibrutinib (drug), Correlative laboratory samples (other), quality of life assessment (other)
- Dates
- Started 2012-05-21; completion 2026-10-31
- Results posted
- Yes
This is a Phase II, single institution open-label, non-randomized monotherapy study to evaluate the clinical efficacy and durable disease control of PCI-32765 administered to patients with relapsed/refractory CLL/SLL/PLL of all risk categories with patients having deletion 17p13 independently evaluated.
From ClinicalTrials.gov, last updated 2026-04-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1.0M in research payments for this study in 2025 (3 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.